Compare Orion Office REIT Inc (ONL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Sana Biotechnology Inc — how do they compare? Orion Office REIT Inc trades at $2.62 (market cap $151.74M), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Sana Biotechnology Inc is far larger — about 5.8× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ONL | SANA | |
|---|---|---|
Market Cap | $151.74M | $879.40M |
Sector | Real Estate | Health |
52-Week High | $3.04 | $5.92 |
52-Week Low | $1.93 | $2.68 |
Enterprise Value | $635.39M | $853.59M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.67, up 1.52% with mixed technical signals showing bullish oscillators but bearish moving averages. The company faces significant fundamental challenges with revenue declining from $208M in 2022 to $147.65M in 2025 and deep net losses widening to -$139.31M. However, strategic reviews with Wells Fargo and JPMorgan and recent refinancing extensions provide some stability amid ongoing portfolio repositioning toward dedicated use assets.
The outlook remains challenging with persistent losses and declining revenue, though the strategic review and deleveraging progress offer potential catalysts. Key risks include execution of asset sales, office market headwinds, and negative cash flow from operations. Analyst sentiment is divided with 50% buy and 50% hold ratings, reflecting uncertainty about the turnaround strategy's success.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
